China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that the National Medical Products Administration (NMPA) has accepted a Category III market filing for its wholly owned subsidiary Viora Ltd’s V20 optical radiofrequency therapy instrument. This development marks a significant step forward for the company’s entry into the Chinese medical aesthetic market.
V20: A Multifunctional Aesthetic Operation Platform
The V20 is a state-of-the-art multifunctional medical aesthetic operation platform that integrates radio frequency (RF) and intense pulsed light (IPL) energy sources. Already approved in the US and Europe, the V20 features proprietary technologies such as CORE bipolar RF and PCR intense pulsed light, setting it apart in the field of medical aesthetics.
Customizable Treatment Solutions and Applications
The V20 can be equipped with multiple operating handles, including V-IPL and V-ST, allowing for flexible matching with exclusive treatment plans tailored to different populations and skin types. This comprehensive solution addresses a range of aesthetic concerns, including skin tightening, hair loss, vascular and pigmentation disorders, acne, and more.-Fineline Info & Tech
